摘要
目的 研究非小细胞肺癌(non-small-cell lung cancer，NSCLC)患者外周血中白细胞介素(interleukin，IL)-35的表达水平及临床意义。 方法 收集2017年6月至2021年12月合肥市第八人民医院呼吸内科56例NSCLC患者以及30例健康志愿者外周血，采用酶联免疫吸附试验(enzyme-linked immunosorbent assay，ELISA)检测IL-35水平；采用反转录聚合酶链反应(RT-PCR)方法检测P35 mRNA和EB病毒诱导基因3(Epstein-Barr virus induced gene 3, EBI3) mRNA表达水平；采用流式细胞术检测调节性T细胞(regulatory T cells，Tregs)的表达水平；分析IL-35与临床病理征和疗效的相关性。 结果 56例NSCLC患者外周血中IL-35、P35 mRNA、EBI3 mRNA和Tregs表达水平相比对照组均明显升高，差异具有统计学意义[IL-35：(124.58±36.41)pg/mL比(31.38±15.34)pg/mL；P35 mRNA: (53.19±7.69)比(15.12±6.91) EBI3 mRNA: (23.18±3.41)比(6.16±1.93)；Tregs: (23.18±3.41) %比(6.16±1.93) %, t值分别为14.72，9.34，4.99，8.39, P值均<0.05]；Ⅲ-Ⅳ患者IL-35水平显著高于Ⅰ-Ⅱ患者，差异具有统计学意义[(135.81±38.88)pg/mL比(115.23±31.21)pg/mL t＝4.44, P<0.05]；伴有淋巴结转移患者相比无淋巴结转移患者IL-35水平亦显著升高，差异具有统计学意义[(141.81±39.71)pg/mL比(112.13± 32.61)pg/mL，t＝3.67, P<0.05]；IL-35和P35 mRNA水平与Tregs水平呈正相关(r值分别为0.761，0.663, P值均<0.05)；经过治疗后，IL-35、P35 mRNA、EBI3 mRNA表达水平显著下降，差异具有统计学意义[IL-35：(132.53±37.12)pg/mL比(56.18±19.35)pg/mL, P35 mRNA: (61.11±7.98)比(25.42±6.12), EBI3 mRNA: (28.14±4.25)比(12.17±2.67),t值分别为31.97，22.35，9.03，P值均<0.05]。 结论 IL-35表达增加可能加速NSCLC患者的进展和转移；IL-35可作为评估NSCLC疾病状态和疗效的标志物。 Objective To study the expression and clinical significance of interleukin-35 in patients with non-small cell lung cancer(NSCLC). Methods The peripheral blood of 56 patients with NSCLC and 30 healthy volunteers from June 2017 to December 2021 in the department of respiratory medicine of the Eighth People's Hospital of Hefei City were collected. The levels of IL-35 were detected by enzyme-linked immunosorbent assay (ELISA). The levels of P35 mRNA and EBI3 mRNA were detected by reverse transcription-polymerase chain reaction (RT-PCR). The levels of regulatory T cells (Tregs) were detected by flow cytometry. The relationship between IL-35 and clinical features and treatment outcome were analyzed. Results The levels of IL-35, P35 mRNA, EBI3 mRNA and Tregs in peripheral blood of 56 NSCLC patients were significantly higher than those in the control group [IL-35: (124.58±36.41)pg/mL vs (31.38±15.34)pg/mL, P35 mRNA: (53.19±7.69) vs (15.12±6.91), EBI3 mRNA: (23.18±3.41) vs (6.16±1.93), Tregs: (23.18±3.41) % vs (6.16±1.93) %, t values were 14.72, 9.34, 4.99, 8.39, all P values<0.05]. The level of IL-35 in patients with Ⅲ-Ⅳ was significantly higher than that in patients with Ⅰ-Ⅱ [(135.81 ±38.88) pg/mL vs (115.23 ±31.21) pg/mL,t=4.44, P<0.05]. Compared with patients without lymph node metastasis, the level of IL-35 was significantly higher in patients with lymph node metastasis [(141.81±39.71)pg/mL vs (112.13± 32.61)pg/mL,t=3.67, P<0.05] . IL-35 and P35 mRNA levels were positively correlated with Tregs (r values were 0.761, 0.663, both P values<0.05). After treatment, IL-35, P35 mRNA and EBI3 mRNA expression levels were significantly decreased[IL-35: (132.53±37.12)pg/mL vs (56.18±19.35)pg/mL, P35 mRNA: (61.11±7.98) vs (25.42±6.12), EBI3 mRNA: (28.14±4.25) vs (12.17±2.67),t values were 31.97, 22.35, 9.03, all P values<0.05]. Conclusion The increased expression of IL-35 may contribute to the progression and metastasis of NSCLC patients. IL-35 can be used as a marker to assess the disease status and treatment outcome of NSCLC patients.
Abstract
Objective To study the expression and clinical significance of interleukin-35 in patients with non-small cell lung cancer(NSCLC). Methods The peripheral blood of 56 patients with NSCLC and 30 healthy volunteers from June 2017 to December 2021 in the department of respiratory medicine of the Eighth People's Hospital of Hefei City were collected. The levels of IL-35 were detected by enzyme-linked immunosorbent assay (ELISA). The levels of P35 mRNA and EBI3 mRNA were detected by reverse transcription-polymerase chain reaction (RT-PCR). The levels of regulatory T cells (Tregs) were detected by flow cytometry. The relationship between IL-35 and clinical features and treatment outcome were analyzed. Results The levels of IL-35, P35 mRNA, EBI3 mRNA and Tregs in peripheral blood of 56 NSCLC patients were significantly higher than those in the control group [IL-35: (124.58±36.41)pg/mL vs (31.38±15.34)pg/mL, P35 mRNA: (53.19±7.69) vs (15.12±6.91), EBI3 mRNA: (23.18±3.41) vs (6.16±1.93), Tregs: (23.18±3.41) % vs (6.16±1.93) %, t values were 14.72, 9.34, 4.99, 8.39, all P values<0.05]. The level of IL-35 in patients with Ⅲ-Ⅳ was significantly higher than that in patients with Ⅰ-Ⅱ [(135.81 ±38.88) pg/mL vs (115.23 ±31.21) pg/mL,t=4.44, P<0.05]. Compared with patients without lymph node metastasis, the level of IL-35 was significantly higher in patients with lymph node metastasis [(141.81±39.71)pg/mL vs (112.13± 32.61)pg/mL,t=3.67, P<0.05] . IL-35 and P35 mRNA levels were positively correlated with Tregs (r values were 0.761, 0.663, both P values<0.05). After treatment, IL-35, P35 mRNA and EBI3 mRNA expression levels were significantly decreased[IL-35: (132.53±37.12)pg/mL vs (56.18±19.35)pg/mL, P35 mRNA: (61.11±7.98) vs (25.42±6.12), EBI3 mRNA: (28.14±4.25) vs (12.17±2.67),t values were 31.97, 22.35, 9.03, all P values<0.05]. Conclusion The increased expression of IL-35 may contribute to the progression and metastasis of NSCLC patients. IL-35 can be used as a marker to assess the disease status and treatment outcome of NSCLC patients.
万方数据